Xcelience Expands its Early Drug Development Capabilities
The Tampa-based CRO is first to acquire next generation Xcelodose

Tampa, FL January 23, 2008 – Xcelience, LLC, a leading pharmaceutical formulation development company, becomes the first Contract Research Organization in North America to purchase the Xcelodose 600 S precision powder micro-doser and automated encapsulator, manufactured by Capsugel.

The S model fills at speeds of over 600 capsules an hour at 50% greater throughput than its predecessor, the Xcelodose 600. "We are very pleased to continue our work with Xcelience and to see them be the first company in the US to order our newest generation of Xcelodose,” says David Edwards, Director of Pharmaceutical Technology, Capsugel.

The CRO, which has grown exponentially since its inception, continues on its path to perpetual growth. “Adding to Xcelience’s arsenal of tools for assisting our clients to accelerate their early drug development pipelines is paramount to our strategic philosophy,” says Randall Guthrie, Vice President.

In addition to expanding operations in 2007 with the acquisition of a new facility, the company boasts an array of new equipment to further amplify its vast capabilities. "Xcelience has built up a wealth of drug development experience since we bought the first Xcelodose in 2005,” says Derek Hennecke, President and CEO. Sponsors have been drawn to our speed in helping get them to the clinic. The new model is faster and will add to our responsiveness time.”

The Xcelodose 600 S is expected to debut at Xcelience as early as May 2008.